Company intelligence / Profile preview
GlyProVac
Odense, Denmarkglyprovac.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GlyProVac is developing GPV02, a maternal vaccine targeting E. coli for prevention of neonatal sepsis. The company received CARB-X funding of $467,000 in February 2024 to support this development.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Vaccines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)
Beyond the preview
Go deeper on GlyProVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlyProVac.